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Abstract: Pre-diabetes and diabetes are strongly associated with periodontal disease (gingivitis
and periodontitis), and these conditions are known to upregulate aMMP-8 in inflamed gingiva and
oral fluids. Thus, it would be feasible to screen for prediabetes and diabetes at the dental office
by chairside tests. Chair-side assessment of HbA1c and a quantitative point-of-care (PoC) active
matrix metalloproteinase (aMMP)-8 oral rinse immunotest developed for periodontal diseases, were
performed on patients (n = 69) attending a Periodontology University Clinic who fulfilled the criteria
for testing according to the screening questionnaire of the Centers for Disease Control and Prevention,
USA. Clinical parameters of periodontal disease were also recorded with an automated probe.
Twenty seven-point-five percent of the subjects were found with previously unknown hyperglycemia
(HbA1c ≥ 5.7%). There was a statistically-significant positive association between the aMMP-8test
and prediabetes (p < 0.05, unadjusted and adjusted for BMI and age ≥ 45 years logistic regression
models). The dental setting is suitable for opportunistic screening for undiagnosed diabetes and
pre-diabetes and point-of-care HbA1c, especially when combined with aMMP-8 assessment by dental
professionals, being convenient and effective.
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1. Introduction
Pre-diabetes and diabetes are associated with an increased rate of initiation, progression, and
severity of periodontal disease (gingivitis and periodontitis) in the oral cavity, and this relationship
has been established at the pathophysiological and epidemiological level [1–4]. These conditions are
known to upregulate aMMP-8 in inflamed gingiva and oral fluids [5,6]. It has been suggested that
screening for prediabetes/diabetes is feasible at dental clinics especially for patients with periodontal
disease [7–11]. Therefore, it would be practical and economical to link chair-side/point-of-care (PoC)
testing to the diagnostic examination for periodontitis and screening for prediabetes/diabetes at the
dentist’s office, since it has been shown that patients meet oral health care professionals on a more
regular basis compared to their visits to a physician [12].
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2. Materials and Methods
Chair-side assessment of HbA1c was performed in a sample of adult patients (n = 69) attending a
Periodontology University Clinic. This study was approved by the Ethics Committee of the School of
Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece (#64, 12/June/2018). All procedures
performed in the studies involving human participants were in accordance with the ethical standards
of the institutional and/or national research committee and with the 1964 Helsinki declaration and
its later amendments or comparable ethical standards and informed consent was obtained from all
individual participants included in the study. Patients fulfilled the criteria for testing according to
the screening questionnaire of the Centers for Disease Control and Prevention, (CDC) USA [13]. The
Cobas Roche b101® diagnostic system was used for the measurement of HbA1c in capillary blood.
Matrix metalloproteinase (MMP)-8 (neutrophil collagenase-2) levels in its active form (aMMP-8) in
the collected oral rinses were analyzed quantitatively by the chair-side/PoCPerioSafe® immunotest
accompanied by the digital reader ORALyzer® according to the manufacturer’s instructions [14,15].
For verification, oral rinses were analyzed by Western immunoblots utilizing specific polyclonal
antibodies for MMP-1, -8, and -13 [16]. Body mass index (BMI), age, level of education, and smoking
were also recorded. Clinical periodontal and oral health parameters including probing depth, clinical
attachment loss, bleeding on probing (BOP), and presence/absence of plaque were assessed for six
surfaces of each tooth, excluding third molars, with an automated probe (Florida probe, Florida Probe
Corporation, Gainesville, FL, USA).
Statistical Methods
Statistical analyses were performed with the SPSS Base 25.0. Statistical Software Package (SPSS
Inc., Chicago, IL, USA). Association between the aMMP-8 PoC test (PerioSafe®/ORALyzer®) and
prediabetes was assessed by logistic regression analysis (both unadjusted and adjusted for BMI and
age ≥ 45 years old). The receiver operating curve (ROC) and area under the ROC curve (AUC) were
used to offer an example for the ability of the aMMP-8 PoC test, in combination with some prediabetes
risk factors, to classify patients with and without prediabetes. Statistical significance was determined
with p-values ≤ 0.05.
3. Results
Patient characteristics and periodontal parameters are presented in Table 1. Twenty
seven-point-five percent of the subjects tested were found to have previously unknown hyperglycemia
(HbA1c ≥ 5.7%). There was a statistically-significant positive association between the aMMP-8 PoC test
(PerioSafe®/ORALyzer®) and prediabetes (defined here as HbA1c ≥ 5.7%) (p < 0.05), but not between
BOP and prediabetes (p > 0.05) (Table 2). This was the result from both unadjusted and adjusted (for
BMI and age ≥ 45 years) logistic regression models; BMI and age ≥ 45 years are known risk factors for
prediabetes. A significant positive association between the aMMP-8 PoC test and periodontal condition
(Stage I/II, Grade A–C) (p < 0.05), according to the 2018 classification of periodontal diseases [3] and
also between BOP and periodontal condition (Stage I/II, Grade A–C) (p < 0.01) was also observed
(Table 1). This was the case in both unadjusted and adjusted (for smoking, gender, age, and education)
logistic regression models. Using BMI and age ≥ 45 years in a logistic regression model produced
AUC = 0.683 (p = 0.020) in ROC analysis, while adding the aMMP-8 PoC test into that model produced
AUC = 0.759 (p = 0.001)
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Table 1. Patient characteristics and periodontal parameters (n = 69).
Prediabetes HbA1c ≥ 5.7 Periodontal Condition
HbA1c < 5.7 HbA1c ≥ 5.7 p-Value Healthy Stage I/II,Grade A–C p-Value
Sex (N)
0.387 a 0.907 aWomen 18 9 8 19
Men 32 10 13 29
Age mean (SD) 48.94 (11.59) 56.37 (11.91) 0.036
b
0.027 c
46.29 (14.14) 53.13 (10.51) 0.045
b
0.056 c
Education level (N)
Elementary 1 1
0.038 a
0 2
<0.001 a
1 27
Middle 15 13 7 2
Post graduate studies 8 1
0 4
13 13Technical school 4 0
University 22 4
Annual dental visit (N)
0.344 a 0.945 aYes 30 9 12 27
No 20 10 9 21
Prediabetes HbA1c ≥5.7 (N)
– 0.027 aYes 0 19 2 17
No 50 0 19 31
HbA1c (mean, SD) 5.15 (0.33) 6.27 (0.90) <0.001
b
<0.001 c
5.30 (0.31) 5.53 (0.86) 0.287
b
0.099 c
eAG (mean, SD) 105.26 (5.44) 133.32(26.00)
<0.001 b
<0.001 c
107.17 (8.12) 118.05(23.32)
0.049 b
0.012 c
Age ≥ 45 years (N)
0.431 a 0.212 aYes 34 15 13 36
No 15 4 8 11
BMI (mean, SD) 29.14 (4.03) 32.21 (5.69) 0.046
b
0.041 c
29.25 (4.12) 30.33 (4.97) 0.525
b
0.352 c
Smoking (N)
0.849 a 0.096 aYes 17 6 4 19
No 33 13 17 29
Toothcount (mean, SD) 25.46 (2.84) 23.89 (3.28) 0.029
b
0.077 c
26.53 (1.86) 24.38 (3.22) 0.004
b
0.001 c
4-mm pocket count (mean, SD) 37.50 (38.17) 52.79 (41.12) 0.182
b
0.170 c
6.00 (6.53) 57.33 (37.39) <0.001
b
<0.001 c
5-mm pocket count (mean, SD) 19.58 (29.50) 28.53 (30.06) 0.081
b
0.275 c
0.95 (1.99) 31.27 (31.46) <0.001
b
<0.001 c
≥6-mm pocket count (mean, SD) 7.28 (13.17) 9.84 (14.63) 0.119 b
0.510 c
0.24 (0.70) 11.38 (15.04) <0.001
b
<0.001 c
BOP (%) (mean, SD) 62.66 (22.96) 64.92 (24.80) 0.762
b
0.732 c
48.03 (27.86) 69.95 (17.52) <0.001
b
0.003 c
Plaque (%) (mean, SD) 61.97 (23.73) 57.70 (25.54) 0.406
b
0.533 c
48.91 (25.02) 65.99 (22.02) 0.010
b
0.011 c
N: frequency; SD: standard deviation; BMI: body mass index; BOP: bleeding on probing. a Mann–Whitney U-test
(exact, 2-sided). b Pearson Chi-squared test (asymptotic, 2-sided). c Welch t-test.
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Table 2. Unadjusted odds ratios (OR) from logistic regression analysis results showing the association between the active MMP-8 (aMMP-8) point-of-care test
(PerioSafe®/ORALyzer®)and prediabetes/periodontal condition (Stage I/II, Grade A–C) [2] and between bleeding on probing (BOP %) and prediabetes/periodontal
condition (Stage I/II, Grade A–C).
Prediabetes HbA1c ≥ 5.7 Periodontal Condition (Stage I/II, Grade A–C)
Unadjusted Adjusted (BMI, Age ≥45 years) Unadjusted Adjusted (Smoking)
Adjusted (Smoking,
Gender)
Adjusted (Smoking,
Gender, Age)
Adjusted (Smoking,
Gender, Age,
Education)
OR (CI 95%), p-value OR (CI 95%), p-value OR (CI 95%), p-value OR (CI 95%), p-value OR (CI 95%), p-value OR (CI 95%), p-value OR (CI 95%), p-value
aMMP-8 (PerioSafe-ORALyzer®) 1.036 (1.007–1.066), 0.016 1.035 (1.003–1.067), 0.031 1.101 (1.012–1.196), 0.025 1.102 (1.013–1.199), 0.024 1.103 (1.013–1.201), 0.024 1.109 (1.015–1.213), 0.023 1.119 (1.005–1.246), 0.040
BOP% 1.004 (0.981–1.028), 0.717 1.007 (0.982–1.032), 0.584 1.049 (1.019–1.079), 0.001 1.047 (1.017–1.078), 0.002 1.047 (1.017–1.078), 0.002 1.046 (1.014–1.080), 0.005 1.044 (1.006–1.084), 0.022
HbA1c ≥ 5.7% 5.210 (1.081–25.104),0.040
5.666 (1.148–27.957),
0.033
6.046 (1.188–30.763),
0.030
4.550 (0.863–23.993),
0.074
3.396 (0.393–29.356),
0.267
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Moreover, we found a significant association between periodontal condition (Stage I/II, Grade
A–C) and prediabetes in unadjusted and some of the adjusted logistic regression models (Table 1).
This suggests that prediabetes may have a negative effect on periodontal condition and vice versa.
Western immunoblot and aMMP-8 oral rinse immunotest analysis utilizing independent and specific
polyclonal and monoclonal antibodies for aMMP-8 disclosed and verified that MMP-8 was elevated,
activated, and fragmented in the diabetic mouth rinse samples (Figure 1). Hardly any MMP-1 or
MMP-13 immunoreactivities were detected in these diabetic oral rinse samples (Figure 1). No MMP-1,
-8, or -13 immunoreactivities could be detected in the systemically- and periodontally-healthy control
oral rinses (Figure 1).
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4. Discussion
Periodontal disease in the form of gingivitis and periodontitis is widespread and significantly
affects both individual welfare and healthcare systems. It is also important to report that a link between
the presence of periodontitis and negative consequences for general health has also emerged. Extensive
epidemiological data have shown that periodontal disease increases the risk of poor glycemic control
in patients with type 2 diabetes mellitus (T2DM), as well as diabetes complications and associated
morbidity, due to the release of bacterial products and inflammatory mediators from periodontal
pockets into the bloodstream [1,2,17]. Findings of the present study suggest that screening at the dental
office for prediabetes/diabetes based on a validated questionnaire (such as the one suggested by CDC)
is greatly enhanced by the aMMP-8 chair-side/PoC testing. Therefore, it is suggested that this chairside
test has an important value in assisting both oral and medical health care professionals in identifying
patients that are not only at risk of periodontitis, but also at risk of developing T2DMor having an
existing diabetes condition. This low-cost translational PoC-diagnostic procedure can be done on-line
chair-side visually and/or quantitatively in 5 min at the dentist’s office. Dental patients who fulfill
questionnaire-based validated criteria for diabetes will benefit from the aMMP-8 PoC test when used
in combination with other known risk factors.
In line with previous reports, this study provides further supporting evidence that the dental
setting is ideal for opportunistic screening for diabetes and that point-of-care HbA1c, especially when
combined with aMMP-8 assessment by dental professionals, is convenient and effective at identifying
undiagnosed diabetes and pre-diabetes.
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5. Conclusions
Findings from the present study translationally and economically linked medical and dental
professionals regarding global screening for both prediabetes/diabetes and periodontitis. Further
studies, with larger subject samples, are required in order to establish this approach in clinical settings.
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